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78BACKGROUND & AIMS:R
79
80Despite signiﬁcant advances in the treatment of Crohn’s disease (CD), most patients still develop
stricturing or penetrating complications that require surgical resections. We performed a sys-
tematic review of mechanisms and potential treatments for tissue damage lesions in CD patients.81
82METHODS:83
84
85We searched the PubMed, MBASE, and Cochrane databases from September 2016 through July
2017 for full-length articles on CD, ﬁbrosis, damage lesions, mesenchymal stem cells, and/or
treatment. We also searched published conference abstracts and performed manual searches of






93Mechanisms of intestinal damage in patients with CD include ﬁbroblast proliferation and
migration, activation of stellate cells, recruitment of intestinal or extra-intestinal ﬁbroblast, and
cell trans-differentiation. An altered balance of metalloproteinases and tissue inhibitors of
metalloproteinases might contribute to ﬁstula formation. Treatment approaches that reduce
excessive transforming growth factor beta (TGFB) activation might be effective in treating
established intestinal damage. Stem cell therapies have been effective in tissue damage lesions
in CD. Particularly, randomized controlled trials have shown local injections of mesenchymal
stem cells to heal perianal ﬁstulas.94
95CONCLUSION:
96
97In a systematic review of mechanisms and treatments of bowel wall damage in patients with CD,
we found a need to test drugs that reduce TGFB and increase healing of transmural damage
lesions and to pursue research on local injection of mesenchymal stem cells.9899Keywords: IBD; Inﬂammatory Bowel Disease; Treatment Outcomes; Inﬂammation.
100
101Abbreviations used in this paper: AT, adipose tissue; BMP-7, bone
morphogenetic protein 7; CD, Crohn’s disease; CTGF, connective tissue
growth factor; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal
transition; HGF, hepatocyte growth factor; IBD, inﬂammatory bowel dis-
ease; IGF, insulin-like growth factor; IL, interleukin; MMP, matrix metal-
loprotease; MSC, mesenchymal stem cell; PPAR-g, peroxisome
proliferator–activated receptor gamma; ROCK, rho-associated protein
kinase; SMA, smooth muscle actin; TC, transitional cells; TGF-b, trans-
forming growth factor b; TIMP, tissue inhibitor of metalloproteinase; TNF-
a, tumor necrosis factor a; UC, ulcerative colitis.

















116Inﬂammatory bowel diseases (IBDs) are chronicinﬂammatory disorders that comprise Crohn’s
disease (CD) and ulcerative colitis (UC). The incidence
of IBD is rising worldwide, increasing the burden on the
patients and health care system.1 CD is characterized by
periods of clinical remission alternating with periods of
relapse reﬂected by recurrent clinical symptoms. Per-
sisting inﬂammation is believed to trigger bowel dam-
age that, over time, culminates in the development of
chronic deep ulcerations, ﬁbrostenotic strictures, ab-
scesses, or ﬁstulae. These complications frequently lead
to an altered intestinal function and represent the main
cause for recurrent surgical resections, which in turn
can lead to disability and impact social or professional
life.2EV 5.5.0 DTD  YJCGH55952_proof  1The recent acknowledgement that CD is a progressive
and destructive disease has led to the development of
new disease indexes, such as the Lemann index0 September 2018  3:08 pm  ce OB




















































































































232measuring cumulative bowel damage over time3 and the
IBD Disability Index.4,5 In parallel to this, the treatment
paradigm is currently shifting in CD from pure symptom
control and improvement of quality of life, toward a
blockade of disease progression and the improvement of
long-term disease outcomes by reducing luminal struc-
tural damage, disability, and long-term disease sequelae.
Modifying the natural history of CD remains a major
clinical challenge, and the rate of ﬁbrostenotic and ﬁs-
tulizing complications leading to surgery remains high.2
As currently available CD drugs fail to effectively treat
structural intestinal damage, a better understanding of
the underlying pathophysiology is a necessity to further
allow the identiﬁcation of new therapeutic targets and
the development of novel treatment options.
Methods
A literature review of the computerized databases
Medline, using PubMed, Embase, and Cochrane, was
conducted between September 2016 and July 2017. To
increase sensitivity, searches using both free text and
MeSH terms were used. MeSH terms included “Crohn’s
disease AND Fibrosis” OR Crohn’s disease AND damage
lesions” OR “Crohn’s disease AND mesenchymal stem
cells” OR “Crohn’s disease AND ﬁbrosis AND treatment”.
Abstracts judged pertinent to the review were identiﬁed;
key aspects were recorded; and full-length articles were
selected from relevant abstracts. A secondary bibliog-
raphy was developed from the references cited in the
selected full-length articles, and additional PubMed
searches were performed to expand the concepts
developed in these articles. The number of abstracts
cited by PubMed from January 1960 to July 2017 and
reviewed for pertinence to this review during the pri-
mary and secondary searches was 1406.
Additionally, we included published conference ab-
stracts and used manual searches for all references
among relevant articles and reviews. Conference ab-
stracts from 2010 to 2016, from United European
Gastroenterology Week, Digestive Disease Week, and the
Congress of the European Crohn’s and Colitis Organisa-
tion were screened. Furthermore, experts in the ﬁeld
were contacted for information regarding nonpublished
studies.
Pathophysiology of Intestinal Damage in
CD: A Source of New Therapeutic
Targets and Strategies
The pathogenesis of stenoses and ﬁstulizing lesions
may share several common pathways, given their close
clinical association. Transmural lesions and in particular
ﬁbrostenosing strictures, are the consequence of exacer-
bated tissue remodeling, leading to the uncontrolled
production of extracellular matrix (ECM) components,
ultimately resulting in obstructive lesions. More than 95%REV 5.5.0 DTD  YJCGH55952_proof  1of intra-abdominal ﬁstulae seem to develop within or at
the proximal end of a stricture, and appear to traverse the
muscular layer along piercing vessels, suggesting that
mechanical factors (eg, intraluminal pressure) might
contribute to the development of ﬁstulae, even though
prospective evaluations are missing.6
During chronic inﬂammation in CD, the epithelial and
endothelial barriers are severely disrupted, leading to
the activation of the innate and adaptive immune sys-
tems with release of proﬁbrotic cytokines, growth fac-
tors, and chemokines that together result in the
activation of mesenchymal cells. Once mesenchymal cells
have become activated, they produce proﬁbrotic factors
in turn eliciting excessive ECM deposition and architec-
tural distortion even in the absence of continued
inﬂammation.7 The main mechanisms involved in
ﬁbrosis and bowel wall damage in CD are represented in
Figure 1.Role of Epithelial Cells and the Epithelial-to-
Mesenchymal Transition
An increasing amount of research indicates that
injured epithelial cells are critical drivers of ﬁbrogenic
process via the acquisition of a proﬁbrotic phenotype.
Epithelial cells are characterized by an inherent plas-
ticity. The process through which epithelial cells take on
the typical mesenchymal cell morphology is known as
epithelial-to-mesenchymal transition (EMT).8,9 During
this transition, epithelial cells lose typical epithelial fea-
tures and gain mesenchymal morphology, markers, and
function. The transition of epithelial cells to a proﬁbro-
genic phenotype is triggered by the transforming growth
factor b (TGF-b)/SMAD pathway, through the tight
interaction with other signaling pathways including nu-
clear factor-kappa B, bone morphogenetic protein 7
(BMP-7), Wnt, or Notch.9 Overall, multiple other cyto-
kines or growth factors, including insulin-like growth
factor (IGF) 1 and IGF-2, epidermal growth factor,
ﬁbroblast growth factor 2, and tumor necrosis factor a
(TNF-a), but also reactive oxygen species, ﬁbronectin,
and ﬁbrin, may promote EMT. Moreover, animal models
of tissue ﬁbrosis have highlighted the involvement of
new transcriptional factors to the already complex EMT-
inducing system, such as zinc ﬁnger E-box-binding
homeobox 1 or Snail.10,11 The integrin aVb6, mainly
expressed by epithelial cells,12 is also an important
in vivo activator of TGF-b in the lung and plays signiﬁ-
cant roles in the development of pulmonary ﬁbrosis.13
Indeed, it has been shown in murine radiation-induced
lung ﬁbrosis that aVb6-mediated TGF-b activation is
required to induce lung ﬁbrosis, and also that an anti-
aVb6 therapy could be effective to prevent ﬁbrosis.
Aside the role of EMT in ﬁbrogenesis, studies have
shown that CD-associated intestinal ﬁstula might also be
inﬂuenced by EMT.14 In a study investigating intestinal
















Figure 1. Pathophysiology of transmural lesions in Crohn’s disease. Fibrosis progression (red) and ﬁstula formation (brown),
and repair (green). ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; IEC, intestinal epithelial cell; IL,
interleukin; MMPs, matrix metalloproteases; MSCs, mesenchymal stem cells; TC, transitional cells; TGF-b, transforming
growth factor b; TIMPs, tissue inhibitors of metalloproteinases; TNF-a, tumor necrosis factor a.




















































































































348epithelialization of the ﬁstula tract was found in a sub-
fraction of patients. Interestingly, a novel cell type, called
transitional cells (TCs), carrying mesenchymal or
myoﬁbroblast-like features, has been described,15 sug-
gesting epithelial-to-mesenchymal transformation.16
These TCs express both epithelial cell markers such as
cytokeratin-8 and cytokeratin-20 and mesenchymal
markers such as vimentin and a-smooth muscle actin
(SMA). High expression levels of Slug, TGF-b, and b6-
integrin were also observed in TCs, and interleukin
(IL-13) may play a central role in EMT during ﬁstula
formation.16
Role of Mesenchymal Cells
Mesenchymal cells can be considered the key exec-
utor of ﬁbrogenesis given their role as potent inducer of
ECM-protein production. Several cell populations may
serve as precursors of myoﬁbroblasts in CD. Increased
proliferation and migration of resident ﬁbroblasts, as
well as the recruitment of bone marrow–derived ﬁ-
broblasts, stellate cells, or pericytes, comprises differentREV 5.5.0 DTD  YJCGH55952_proof  1sources of myoﬁbroblasts in intestinal ﬁbrosis. In
addition, cellular transdifferentiation or EMT and
endothelial-to-mesenchymal transition further contrib-
utes to the enlargement of the pool of myoﬁbroblasts
(Figure 1).17 In the intestine, there are 3 main types of
resident mesenchymal cells, including smooth muscle
cells, ﬁbroblasts, and subepithelial myoﬁbroblasts, a
subtype of stromal cells located under the epithelial
layer that communicate in a paracrine fashion with
surrounding cells, and which play important roles in the
mucosal regeneration, repair, and ﬁbrosis.17 In the in-
testine of patients with CD, myoﬁbroblast activation can
be modulated by the combined action of a wide variety
of inﬂammatory factors, such as TNF-a, interferon
gamma, TGF-b1, IGF-1, platelet-derived growth factor,
connective tissue growth factor [CTGF], IGFI/II, basic
ﬁbroblast growth factor, IL-1b, IL-6, and IL-13 secreted
by immune and nonimmune cells. The main mediator
promoting ﬁbrogenesis is TGF-b, exerting pleiotropic
functions, such as the overexpression of a-SMA,
contraction of myoﬁbroblasts, or the excessive accu-
























































































































463TGF-b1 signals mainly by a canonical SMAD-based
pathway, supported by evidence demonstrating the ef-
fect of the disruption of the TGF-b/SMAD signaling
pathway on reduced ﬁbrosis, either by the loss of SMAD3
or the increase of the expression of the inhibitory SMAD
(SMAD7). In CD patients, it has been suggested that
activation of an integrin expressed on muscle cells, aVb3,
could increase TGF-b1 levels in intestinal strictures.18
Studies have explored smooth muscle cells isolated
from CD strictures and normal resection margin as well
as from the colon of rats after 42 days of chronic 2,4,6-
trinitrobenzene sulfonic acid–induced colitis. They
showed that latent TGF-b1 was activated by the aVb3
arginylglycylaspartic acid domain in human and rat in-
testinal smooth muscle cells.
A variety of mediators including damage-associated
molecular patterns, DNA, RNA, adenosine triphosphate,
high mobility group box 1 protein, microvesicles, frag-
ments of ECM molecules as well as the Indian hedgehog
(Ihh) and the Wnt/b-catenin pathways have been iden-
tiﬁed to contribute to the complexity and dynamics of
myoﬁbroblast activation.19 Furthermore, the intestinal
microbiota has been revealed to be crucially involved in
the development and progression of intestinal ﬁbrosis or
ﬁstula formation in IBD and the interaction between
pathogen-associated molecular patterns and pattern
recognition receptors, such as Toll-like receptors, is
currently considered a possible crucial event in myoﬁ-
broblast activation.20
Aside from excessive ECM accumulation, a dysregu-
lation of matrix metalloproteinases (MMPs) and their
inhibitors, tissue inhibitors of metalloproteinases
(TIMPs), during active intestinal inﬂammation, by which
myoﬁbroblasts regulate tissue regeneration in IBD, has
been reported. More speciﬁcally, myoﬁbroblasts isolated
from the inﬂamed intestine were shown to be able to
express MMP-1, MMP-2, and MMP-3, as well as TIMP-1.
Increased expression levels of these proteases were
observed in cells isolated from ﬁbrotic areas.21 Early
in vitro studies demonstrated that stimulation of myoﬁ-
broblasts with TNF-a, a well-known IBD key player,
induced the expression of TIMP-1, MMP-1, and MMP-3,
and the secretion of type I and IV collagen.22
In a previous study in CD patients with ﬁstulizing
disease, a strong expression of MMP-3 and MMP-9 was
observed in CD ﬁstula independently of the stage of
inﬂammation. Increased expression levels of MMP-3 and
MMP-9 were detected in mononuclear cells, granulocytes
and ﬁbroblasts. Furthermore, supernatant of untreated
CD ﬁstula colonic lamina propria ﬁbroblasts showed
signiﬁcantly elevated MMP-13 expression levels
compared with nonﬁstula colonic lamina propria ﬁbro-
blasts. In addition, the expression of TIMP-1, TIMP-2, and
TIMP-3 was low around CD ﬁstula.23 Altogether, these
observations suggest that an altered balance in MMP and
TIMP expression levels might critically contribute to
ﬁstula formation.REV 5.5.0 DTD  YJCGH55952_proof  1Interaction Between Epithelial and
Mesenchymal Cells
It is obvious that cells do not operate in isolation, but
rather that their interaction is important. Recent
experimental studies and clinical observations suggest
that an altered crosstalk between colonic epithelial cells
and adjacent subepithelial myoﬁbroblasts may play an
important role in the pathogenesis of ECM remodeling
and inﬂammation associated ﬁbrosis.24 In in vitro
studies on colonic epithelial cells, proinﬂammatory cy-
tokines (IL-1a, TNF-a, interferon gamma) were shown
to induce TGF-b and TIMP-1 expression. Moreover, the
conditioned medium isolated from these cultures
stimulated synthesis of MMP-9 and type I collagen and
also suppressed the migration of subepithelial myoﬁ-
broblasts.24 The concept of epithelial to mesenchymal
interaction has been shown in the context of idiopathic
pulmonary ﬁbrosis between alveolar epithelial cells and
alveolar ﬁbroblasts.25 Indeed, repetitive cycles of
epithelial injury and death stimulated the activation,
proliferation, migration and differentiation of ﬁbro-
blasts to myoﬁbroblasts, through synthesis of TGF-b,
CTGF, sonic hedgehog (Shh), and prostaglandin E2,
resulting in excessive ECM deposition. In turn, these
activated ﬁbroblasts induced alveolar epithelial cell
injury and death by producing angiotensin II and
reactive oxygen species, therefore creating a cycle of
proﬁbrotic epithelial cell-ﬁbroblast interactions.26 All
this evidence in idiopathic pulmonary ﬁbrosis suggests
a decisive involvement of the epithelial-ﬁbroblast in-
teractions in the progression of organ ﬁbrosis that could
also concern intestinal ﬁbrosis.Involvement of Mesenchymal Stem Cells in the
Fibrotic Processes
Mesenchymal stem cells (MSCs) are pluripotent cells
derived from stromal tissue such as bone marrow or
adipose tissue (AT). They may migrate to the intestine
and they exhibit multilineage differentiation capacity and
may mediate immunomodulatory, anti-inﬂammatory,
and regenerative properties.27 MSCs can directly inﬂu-
ence the fate and function of many distinct leukocyte
populations, primarily through the action of soluble
mediators. Lanzoni et al28 demonstrated that intestinal-
derived MSCs are able to induce differentiation and
organization of intestinal epithelial Caco-2 cells in
3-dimensional collagen cultures. The potential role of
these MSCs has also been studied in several experimental
models of ﬁbrosis in the lungs,29 peritoneum,30 skin,31
kidneys,31 and gastrointestinal tract.32 These MSCs act
through several distinct mechanisms including inter-
fering with TGF-b1 pathway, secreting hepatocyte
growth factor (HGF), decreasing collagen deposition, and
modifying secretion of various MMPs and TIMPs.29–400 September 2018  3:08 pm  ce OB
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534Existing and New Treatments as
Potential Candidates for Tissue
Damage Lesions in CD
Several existing drug and cell therapies have been
assessed in animal or human models of pathological
ﬁbrosis, including in the intestine. These potential
treatments for tissue damage lesions are summarized in
Table 1 and their potential site of action on ﬁbrosis and

















































Tranilast. Tranilast is an antiallergic agent that blocks
the release of chemical mediators such as histamine and
prostaglandins from mast cells, and inhibits TGF-b-
induced ECM production and transformation of epithelial
cells.33–35 It has been shown that tranilast, aside from its
role in EMT, has antiﬁbrotic actions in an experimental
model of diabetic rats by reducing TGF-b activity.
Furthermore, it was capable to inhibit ﬁbroproliferative
airway changes and was beneﬁcial in preventing bron-
chiolitis obliterans after lung transplantation in a rat
model of heterotopic tracheal transplantation.35
A case report on a patient with inﬂammatory endo-
bronchial stenosis that was successfully treated by tra-
nilast further corroborated the therapeutic efﬁcacy of
long-term tranilast administration.36 In CD, Oshitani
et al37 evaluated the drug in 24 patients with non-
symptomatic intestinal strictures. Patients were
followed-up prospectively after being allocated either to
200-mg tranilast 3 times daily or to the control group not
receiving the agent. The primary study endpoint was the
development of symptomatic strictures requiring endo-
scopic balloon dilatation, which was performed in 1 pa-
tient in the tranilast group and in 5 patients in the
control group (P ¼ .0034). However, the observed
change in stricture diameter during the follow-up period
was not signiﬁcantly different between both groups.
Spironolactone. Spironolactone is a competitive aldo-
sterone receptor antagonist that is commonly used as an
antiﬁbrotic medication in heart patients, and has proven
to be protective in several rodent models of ﬁbrosis.38
Johnson et al39 have shown that spironolactone medi-
ated antiﬁbrotic actions in isolated human colonic myo-
ﬁbroblasts and repressed TGF-b–mediated induction of
proﬁbrotic genes and proteins. The same group recently
reported, that spironolactone treatment blocked TGF-
b–induced proﬁbrotic gene expression, including ﬁbro-
nectin, and a-SMA protein production in a novel model of
human intestinal organoids.40
Pirfenidone. Pirfenidone is an orally bioavailable
small molecule that exhibits well-documented anti-
ﬁbrotic and anti-inﬂammatory properties in a variety of
animal and in vitro models in different organs, including
ﬁbrosis of the lungs, kidneys, heart, liver, and skin.41REV 5.5.0 DTD  YJCGH55952_proof  1Meier et al42 have investigated the impact of pirfeni-
done treatment on development of ﬁbrosis in a mouse
model of intestinal ﬁbrosis. After administration of pir-
fenidone, a signiﬁcantly decreased collagen layer thick-
ness was revealed as compared with control. In intestinal
ﬁbroblasts TGF-b and MMP-9 were signiﬁcantly
decreased after treatment with pirfenidone as conﬁrmed
by real-time polymerase chain reaction and by Western
blotting.
Cilengitide. Li et al18 showed that increased activa-
tion of TGF-b1 in human CD patients and in TNBS-
induced colitis caused increased collagen production
and that ﬁbrosis could be inhibited by cilengitide, an
arginylglycylaspartic acid–containing aVb3 integrin
inhibitor.
Newly Developed Small Molecules
Peroxisome Proliferator–Activated Receptor Gamma
Agonists. Peroxisome proliferator–activated receptor
gamma (PPAR-g) is a member of ligand-activated tran-
scription factors of nuclear hormone receptor super-
family, which present pleiotropic effects on lipid
metabolism, inﬂammation, and cell proliferation.43
Stimulation of PPAR-g with speciﬁc ligands down-
regulates the CTGF expression, promoting TGF-induced
synthesis of collagen.44 Along this, experimental studies
have shown that PPAR-g agonists attenuate ﬁbrosis in
various organs including the lungs, kidneys, pancreas,
liver, and intestine. These antiﬁbrotic effects are abol-
ished by the use of PPAR-g selective antagonists.45–47
Concerning intestinal inﬂammation, the antiﬁbrotic ef-
fect of a novel aminosalicyate analog able to activate
PPAR-g, named GED-0507-34, was evaluated in mice
with colonic ﬁbrosis induced by dextran sulfate sodium
administration.48 GED-0507-34 improved macroscopic
and microscopic intestinal lesions and reduced the pro-
ﬁbrotic gene expression of a-SMA, collagen, and ﬁbro-
nectin. It also reduced the main TGF-b/SMAD pathway
components and inhibited TGF-b–induced activation of
both ﬁbroblast and intestinal epithelial cell lines. Finally,
GED-0507-34 treatment also reduced the TGF-b expres-
sion in primary human intestinal ﬁbroblasts isolated
from 1 UC patient.
Rho-Associated Protein Kinase Inhibitors. Holvoet
et al49 showed that rho-associated protein kinases
(ROCKs), which play multiple roles in TGF-b1–induced
myoﬁbroblast activation, could be therapeutic targets.
They evaluated the effects of a locally acting ROCK in-
hibitor, named AMA0825 (a highly selective inhibitor of
ROCK 1 and ROCK 2), on intestinal ﬁbrosis using mouse
models of ﬁbrosis (dextran sulfate sodium and adoptive
T cell transfer), and biopsy cultures from CD patients.
ROCK inhibition reversed established ﬁbrosis by inhib-
iting myoﬁbroblast accumulation, expression of proﬁ-
brotic factors, and accumulation of ﬁbrotic tissue without
affecting clinical disease activity and histological
inﬂammation in 2 mouse models of ﬁbrosis. Moreover0 September 2018  3:08 pm  ce OB
Table 1. Studies Evaluating Potential Treatment Options for Intestinal Damage in Crohn’s Disease
Molecule Mechanism of Action Study Design n Efﬁcacy Q10Safety
Tranilast37 Antiallergic agent inhibited
chemical mediators and
TGF-b release
Case control 24 CD patients with small
bowel strictures
There was less hydrostatic
balloon dilatation in tranilast
group
(P ¼ .003).
Reduced white blood cell




Intestinal model of ﬁbrosis using
human intestinal organoids
NA Spironolactone repressed
induction of the ﬁbronectin 1
and a-SMA proteins genes.
NA
GED-0507-3448 PPAR-g modulator DSS colitis mice model 110 mice GED-0507-34 downregulates
colonic expression of a-SMA,
type I–III collagen, TGF-b,
SMAD3, IL-13, and CTGF.
NA
Cilengitide18 aVb3 integrin inhibitor Intestine cells from ileal/
ileocolonic resection






AMA082549 Highly selective inhibitor of
ROCK 1 and ROCK 2
Mouse models of ﬁbrosis (DSS
and adoptive T cell transfer)
NA AMA0825 reversed myoﬁbroblast
accumulation, expression of
proﬁbrotic factors, and
accumulation of ﬁbrotic tissue
in 2 mouse models of ﬁbrosis.
NA
Biopsy cultures from CD patients ROCK inhibitor reduced activation
of myocardin-related
transcription factor and p38
mitogen-activated protein
kinase, and increased
autophagy in ﬁbroblasts, in
intestinal ﬁbrosis from stenotic
CD biopsies.












































































































































































































































































































































































































































Figure 2. Potential treatment options for intestinal damage in Crohn’s disease and their mechanisms of action. Several
molecules have multiple mechanisms of action. Only the most prominent has been highlighted. BMP-7, bone morphogenetic
protein 7; ECM, extracellular matrix; EMT, epithelial-to-mesenchymal transition; HGF, hepatocyte growth factor; IL, interleukin;
MMPs, matrix metalloproteases; MSCs, mesenchymal stem cells; PPAR, peroxisome proliferator–activated receptor; TGF-b,
transforming growth factor b; TNF-a, tumor necrosis factor a.




















































































































812ROCK inhibition reversed intestinal ﬁbrosis from stenotic
CD biopsies, by reducing TGF-b1–induced activation of
myocardin-related transcription factor and p38 mitogen-
activated protein kinase, and by increasing autophagy in
ﬁbroblasts.
Recombinant Factors and Biologics
BMP7 and HGF. EMT can be reverted by the admin-
istration of BMP-7 and HGF.50 In a mouse model of
chronic renal injury, it has been shown that systemic
administration of recombinant human BMP-7 reverses
TGF-b1–induced EMT and leads to repair of severely
damaged renal tubular epithelial cells, in association
with reversal of chronic renal injury.50 HGF is also a
potent antiﬁbrotic cytokine that blocks tubular epithelial
to EMT. It has been reported in human kidney epithelial
cells that HGF blocks EMT by antagonizing TGF-b1’s ac-
tion via upregulating SMAD transcriptional co-repressor
SnoN expression.50REV 5.5.0 DTD  YJCGH55952_proof  1Anti-MMP-9 Antibody. C3M, an MMP-9 degradation
product of type III collagen, have been shown to be
associated with penetrating CD and differentiated pene-
trating CD from other CD subgroups and healthy control
subjects.51 Gofﬁn et al51 have recently assessed the effect
of MMP-9 inhibition in the heterotopic transplant mouse
model of intestinal ﬁbrosis by using anti-MMP-9 anti-
body treatment, CALY-001. Compared with isotype
control–treated group, the anti-MMP-9 antibody–treated
mice presented only partially obstructed intestinal
lumen, with a collagen layer only slightly thicker than
that observed in freshly isolated intestinal samples.
Quantiﬁcation of collagen-speciﬁc amino acid hydroxy-
proline conﬁrmed lower collagen amounts in grafts from
mice treated with anti-MMP-9 antibodies compared with
those treated with isotype control.
Anti-aVb6 Monoclonal Antibodies. Hahm et al52
showed that anti-aVb6 monoclonal antibodies were
able to inhibit accumulation of activated ﬁbroblasts and
deposition of interstitial collagen matrix in a renal0 September 2018  3:08 pm  ce OB

































































877ﬁbrosis model in Alport mice. Madala et al13 showed that
inhibition of the b6 integrin led to a signiﬁcant effect on
the pleural thickening and lung function decline
observed in pulmonary ﬁbrosis of TGF transgenic mice.
STX-100, a humanized monoclonal antibody against aV-
b6 integrin is currently tested in a phase 2 trial in idio-


















































As highlighted in a previous paragraph, recent
studies demonstrate the potential of MSCs to be used
as a new therapeutic strategy to address chronic
inﬂammation–associated tissue damage, including
ﬁbrosis. Autologous and allogeneic MSCs have been
tested in clinical trials in 2 different modalities: local
injections of MSCs to treat ﬁstulizing CD and intrave-
nous infusion to treat luminal inﬂammation.53
Local perianal injections of autologous or allogeneic
AT-MSCs or bone marrow MSCs have shown some efﬁ-
cacy and reassuring safety in several phase I, II, and III
trials.54–56 Until now, more than 200 CD patients with
refractory ﬁstulas have been treated with local injections
of MSCs, resulting in complete response in more than
half of these.54,55 However, only 2 randomized controlled
trials demonstrated the superiority of autologous and
allogeneic MSCs over placebo. The ﬁrst study, a phase II
multicenter, randomized, controlled trial, evaluated stem
cell–based therapy with expanded AT-MSCs in 49 pa-
tients with complex perianal ﬁstulas.57 Patients with
complex perianal ﬁstulas were randomly assigned to
intralesional treatment with ﬁbrin glue or ﬁbrin glue
plus 20 million AT-MSCs. At 8 weeks, ﬁstula healing was
observed in 71% of patients who received AT-MSCs in
addition to ﬁbrin glue, compared with 16% of patients
who received ﬁbrin glue alone (relative risk for healing,
4.43; 95% conﬁdence interval, 1.74–11.27). At 1-year
follow-up, the recurrence rate in patients treated with
AT-MSCs was 18%. Importantly, among the 49 patients
included, 35 had complex perianal ﬁstulae with a cryp-
toglandular origin and only 14 patients had CD, but the
proportion of patients with healing was similar in CD and
non-CD subgroups. Over the long term, with a mean
follow-up of 38 months, among the 12 patients with a
complete ﬁstula closure, 7 remained free of recurrence.
Only 1 adverse event unrelated to the original treatment
was reported.58 The second trial was a randomized
double-blind, parallel-group, placebo-controlled study,
conducted in 49 hospitals in 7 European countries and
Israel.56 A total of 212 CD patients with refractory
complex perianal ﬁstulas were randomly assigned to
receive a single intralesional injection of 120 million
allogeneic AT-MSCs (Cx601) or placebo. A signiﬁcantly
greater proportion of patients treated with Cx601 vs
placebo achieved combined remission at week 24,
deﬁned by clinical assessment of closure of all treated
external openings and absence of collections >2 cmREV 5.5.0 DTD  YJCGH55952_proof  1conﬁrmed by magnetic resonance imaging (53 of 107
[49.5%] vs 36 of 105 [34.3%]; P ¼ .024). A higher pro-
portion of placebo vs Cx601 patients experienced
treatment-related adverse events, mostly anal abscesses
and proctalgia. Recently, authors reported efﬁcacy and
safety of patients treated with Cx601 vs placebo 1 year
after AT-MSCs administration.59 A signiﬁcantly greater
proportion of patients receiving Cx601 vs placebo ach-
ieved combined remission (56.3% vs 38.6%; P ¼ .010)
and clinical remission (59.2% vs 41.6%; P ¼ .013) at
week 52. Rates and types of treatment-related adverse
events were similar in both groups (20.4% for Cx601 vs
26.5% for placebo). All these results underline that
autologous and allogeneic MSCs administration repre-
sents an effective and safe therapy for complex ﬁstulas in
CD that failed to respond to conventional or biological
treatments.
A lower number of trials have been performed with
intravenous injections of MSCs.60,61 These trials have
provided conﬂicting results. No data are currently
available reporting on the speciﬁc effect of intravenous
MSCs injection on stricturing or ﬁstulizing CD. Similarly,
there is no trial available investigating the efﬁcacy of
local MSCs injection in CD lesions other than perianal
ﬁstulae, such as intestinal strictures or chronic unhealed
ulcers.
Conclusion
Persistent high rates of stricturing and ﬁstulizing
complications leading to signiﬁcant bowel damage, sur-
gical resection, and disability in CD patients may lead
physicians to modify their management of CD. There is
an urgent need to develop novel medical treatment op-
tions to stop and reverse proﬁbrotic mechanisms, to
improve transmural damage lesions and change the
chronic progressive disease course. Several small mole-
cules, recombinant factors, monoclonal antibodies, or
MSC therapies targeting TGF-b1–induced pathways, ECM
deposition, and EMT are currently tested in animal
models and clinical trials. Among these, tranilast, PPAR-g
agonists, rho kinase inhibitors, and especially MSC ther-
apy have provided interesting results in CD patients with
irreversible damage lesions, and thus represent the most
promising and available therapies that could be evalu-
ated in the near future in clinical trials. They may
represent the future treatment of stricturing and ﬁstul-
izing CD.0 SepReferences
1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and
prevalence of inﬂammatory bowel disease in the 21st century: a
systematic review of population-based studies. Lancet 2018;
390:2769–2778.
2. Pariente B, Cosnes J, Danese S, et al. Development of the
Crohn’s disease digestive damage score, the Lémann score.
Inﬂamm Bowel Dis 2011;17:1415–1422.tember 2018  3:08 pm  ce OB
928


















































































































10423. Pariente B, Mary J-Y, Danese S, et al. Development of the
Lémann index to assess digestive tract damage in patients with
Crohn’s disease. Gastroenterology 2015;148:52–63.e3.
4. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of
the ﬁrst disability index for inﬂammatory bowel disease based
on the international classiﬁcation of functioning, disability and
health. Gut 2012;61:241–247.
5. Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the
Inﬂammatory Bowel Disease Disability Index in a population-
based cohort. Gut 2017;66:588–596.
6. Oberhuber G, Stangl PC, Vogelsang H, et al. Signiﬁcant asso-
ciation of strictures and internal ﬁstula formation in Crohn’s
disease. Virchows Arch 2000;437:293–297.
7. Lin GG, Scott JG. The mechanisms that mediate the develop-
ment of ﬁbrosis in patients with Crohn’s disease. Inﬂamm Bowel
Dis 2012;100:130–134.
8. Arias AM. Epithelial mesenchymal interactions in cancer and
development. Cell 2001;105:425–431.
9. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal
transition. J Clin Invest 2009;119:1420–1428.
10. Rieder F, Kessler SP, West GA, et al. Inﬂammation-induced
endothelial-to-mesenchymal transition: a novel mechanism of
intestinal ﬁbrosis. Am J Pathol 2011;179:2660–2673.
11. Bachelder RE, Yoon S-O, Franci C, et al. Glycogen synthase
kinase-3 is an endogenous inhibitor of Snail transcription: im-
plications for the epithelial-mesenchymal transition. J Cell Biol
2005;168:29–33.
12. Knight PA, Wright SH, Brown JK, et al. Enteric expression of the
integrin alpha(v)beta(6) is essential for nematode-induced
mucosal mast cell hyperplasia and expression of the granule
chymase, mouse mast cell protease-1. Am J Pathol 2002;
161:771–779.
13. Madala SK, Korfhagen TR, Schmidt S, et al. Inhibition of the
avb6 integrin leads to limited alteration of TGF-a-induced pul-
monary ﬁbrosis. Am J Physiol Lung Cell Mol Physiol 2014;
306:L726–L735.
14. Scharl M, Huber N, Lang S, et al. Hallmarks of epithelial to
mesenchymal transition are detectable in Crohn’s disease
associated intestinal ﬁbrosis. Clin Transl Med 2015;4:1.
15. Bataille F, Klebl F, Rümmele P, et al. Morphological character-
isation of Crohn’s disease ﬁstulae. Gut 2004;53:1314–1321.
16. Scharl M, Frei S, Pesch T, et al. Interleukin-13 and transforming
growth factor b synergise in the pathogenesis of human intes-
tinal ﬁstulae. Gut 2013;62:63–72.
17. Rieder F, Fiocchi C. Intestinal ﬁbrosis in inﬂammatory bowel
disease — Current knowledge and future perspectives.
J Crohns Colitis 2008;2:279–290.
18. Li C, Flynn RS, Grider JR, et al. Increased activation of latent
TGF-b1 by aVb3 in human Crohn’s disease and ﬁbrosis in TNBS
colitis can be prevented by cilengitide. Inﬂamm Bowel Dis 2013;
19:2829–2839.
19. Latella G, Vetuschi A, Sferra R, et al. Localization of anb6
integrin-TGF-b1/Smad3, mTOR and PPARg in experimental
colorectal ﬁbrosis. Eur J Histochem 2013;57:e40.
20. Fiocchi C, Lund PK. Themes in ﬁbrosis and gastrointestinal
inﬂammation. Am J Physiol Gastrointest Liver Physiol 2011;
300:G677–G683.
21. Lakatos G, Sipos F, Miheller P, et al. The behavior of matrix
metalloproteinase-9 in lymphocytic colitis, collagenous colitis
and ulcerative colitis. Pathol Oncol Res 2012;18:85–91.REV 5.5.0 DTD  YJCGH55952_proof  122. Okuno T, Andoh A, Bamba S, et al. Interleukin-1beta and tumor
necrosis factor-alpha induce chemokine and matrix metal-
loproteinase gene expression in human colonic subepithelial
myoﬁbroblasts. Scand J Gastroenterol 2002;37:317–324.
23. Kirkegaard T, Hansen A, Bruun E, et al. Expression and local-
isation of matrix metalloproteinases and their natural inhibitors in
ﬁstulae of patients with Crohn’s disease. Gut 2004;53:701–709.
24. Drygiannakis I, Valatas V, Sfakianaki O, et al. Proinﬂammatory
cytokines induce crosstalk between colonic epithelial cells and
subepithelial myoﬁbroblasts: Implication in intestinal ﬁbrosis.
J Crohns Colitis 2013;7:286–300.
25. Wynn TA. Common and unique mechanisms regulate ﬁbrosis in
various ﬁbroproliferative diseases. J Clin Invest 2007;117:524–529.
26. Lin GG, Scott JG. Fibrosis of two: epithelial cell-ﬁbroblast in-
teractions in pulmonary ﬁbrosis. Biochim Biophys Acta 2012;
100:130–134.
27. Aggarwal S, Pittenger MF. Human mesenchymal stem cells
modulate allogeneic immune cell responses. Blood 2005;
105:1815–1822.
28. Lanzoni G, Alviano F, Marchionni C, et al. Isolation of stem cell
populations with trophic and immunoregulatory functions from
human intestinal tissues: potential for cell therapy in inﬂamma-
tory bowel disease. Cytotherapy 2009;11:1020–1031.
29. Reddy M, Fonseca L, Gowda S, et al. Human adipose-derived
mesenchymal stem cells attenuate early stage of bleomycin
induced pulmonary ﬁbrosis: comparison with pirfenidone. Int J
Stem Cells 2016;9:192–206.
30. Ueno T, Nakashima A, Doi S, et al. Mesenchymal stem cells
ameliorate experimental peritoneal ﬁbrosis by suppressing
inﬂammation and inhibiting TGF-b1 signaling. Kidney Int 2013;
84:297–307.
31. Wu HJ, Yiu WH, Li RX, et al. Mesenchymal stem cells modulate
albumin-induced renal tubular inﬂammation and ﬁbrosis. PLoS
One 2014;9:e90883.
32. Linard C, Busson E, Holler V, et al. Repeated autologous bone
marrow-derived mesenchymal stem cell injections improve
radiation-induced proctitis in pigs. Stem Cells Transl Med 2013;
2:916–927.
33. Shimizu T, Kanai K-I, Kyo Y, et al. Effect of tranilast on matrix
metalloproteinase production from neutrophils in-vitro. J Pharm
Pharmacol 2006;58:91–99.
34. Martin J, Kelly DJ, Mifsud SA, et al. Tranilast attenuates cardiac
matrix deposition in experimental diabetes: role of transforming
growth factor-beta. Cardiovasc Res 2005;65:694–701.
35. Okada Y, Matsumura Y, Shimada K, et al. Anti-allergic agent
tranilast decreases development of obliterative airway disease in
rat model of heterotopic tracheal transplantation. J Heart Lung
Transplant 2004;23:1392–1395.
36. Yanagihara K, Matsuoka K, Hanaoka N, et al. Inﬂammatory
endobronchial stenosis. Ann Thorac Surg 2001;71:698–699.
37. Oshitani N, Yamagami H, Watanabe K, et al. Long-term pro-
spective pilot study with tranilast for the prevention of stricture
progression in patients with Crohn’s disease. Gut 2007;
56:599–600.
38. Nishimura H, Ito Y, Mizuno M, et al. Mineralocorticoid receptor
blockade ameliorates peritoneal ﬁbrosis in new rat peritonitis
model. Am J Physiol Renal Physiol 2008;294:F1084–F1093.
39. Johnson LA, Govani SM, Joyce JC, et al. Spironolactone and
colitis: increased mortality in rodents and in humans. Inﬂamm




















































































































115440. Rodansky ES, Johnson LA, Huang S, et al. Intestinal organoids:
a model of intestinal ﬁbrosis for evaluating anti-ﬁbrotic drugs.
Exp Mol Pathol 2015;98:346–351.
41. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients
with idiopathic pulmonary ﬁbrosis (CAPACITY): two randomised
trials. Lancet 2011;377:1760–1769.
42. Meier R, Lutz C, Cosín-Roger J, et al. Decreased ﬁbrogenesis
after treatment with pirfenidone in a newly developed mouse
model of intestinal ﬁbrosis. Inﬂamm Bowel Dis 2016;22:569–582.
43. Speca S, Giusti I, Rieder F, et al. Cellular and molecular mech-
anisms of intestinal ﬁbrosis. World J Gastroenterol 2012;
18:3635–3661.
44. Zhang G-Y, Cheng T, Zheng M-H, et al. Activation of peroxi-
some proliferator-activated receptor-gamma inhibits trans-
forming growth factor-beta1 induction of connective tissue
growth factor and extracellular matrix in hypertrophic scar ﬁ-
broblasts in vitro. Arch Dermatol Res 2009;301:515–522.
45. Talukdar R, Tandon RK. Pancreatic stellate cells: new target in
the treatment of chronic pancreatitis. J Gastroenterol Hepatol
2008;23:34–41.
46. Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenu-
ates renal interstitial ﬁbrosis and inﬂammation through reduction
of TGF-beta. Lab Investig 2009;89:47–58.
47. Yang L, Stimpson SA, Chen L, et al. Effectiveness of the PPARg
agonist, GW570, in liver ﬁbrosis. Inﬂamm Res 2010;59:
1061–1071.
48. Speca S, Rousseaux C, Dubuquoy C, et al. Novel PPARg
modulator GED-0507-34 Levo ameliorates inﬂammation-driven
intestinal ﬁbrosis. Inﬂamm Bowel Dis 2016;22:279–292.
49. Holvoet T, Devriese S, Castermans K, et al. Treatment of in-
testinal ﬁbrosis in experimental inﬂammatory bowel disease by
the pleiotropic actions of a local rho kinase inhibitor. Gastro-
enterology 2017;153:1054–1067.
50. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts
TGF-beta1-induced epithelial-to-mesenchymal transition and
reverses chronic renal injury. Nat Med 2003;9:964–968.
51. Gofﬁn L, Fagagnini S, Vicari A, et al. Anti-MMP-9 antibody: a
promising therapeutic strategy for treatment of inﬂammatory
bowel disease complications with ﬁbrosis. Inﬂamm Bowel Dis
2016;22:2041–2057.
52. Hahm K, Lukashev ME, Luo Y, et al. Alphav beta6 integrin
regulates renal ﬁbrosis and inﬂammation in Alport mouse. Am J
Pathol 2007;170:110–125.
53. Voswinkel J, Francois S, Simon JM, et al. Use of mesenchymal
stem cells (MSC) in chronic inﬂammatory ﬁstulizing and ﬁbrotic
diseases: a comprehensive review. Clin Rev Allergy Immunol
2013;45:180–192.REV 5.5.0 DTD  YJCGH55952_proof  154. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone
marrow-derived mesenchymal stromal cells in the treatment of
ﬁstulising Crohn’s disease. Gut 2011;60:788–798.
55. Molendijk I, Bonsing BA, Roelofs H, et al. Allogeneic bone
marrow-derived mesenchymal stromal cells promote healing of
refractory perianal ﬁstulas in patients with Crohn’s disease.
Gastroenterology 2015;149:918–927.e6.
56. Panés J, García-Olmo D, Van Assche G, et al. Expanded allo-
geneic adipose-derived mesenchymal stem cells (Cx601) for
complex perianal ﬁstulas in Crohn’s disease: a phase 3 rando-
mised, double-blind controlled trial. Lancet 2016;388:
1281–1290.
57. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-
derived stem cells for the treatment of complex perianal ﬁstula: a
phase II clinical trial. Dis Colon Rectum 2009;52:79–86.
58. Guadalajara H, Herreros D, De-La-Quintana P, et al. Long-term
follow-up of patients undergoing adipose-derived adult stem
cell administration to treat complex perianal ﬁstulas. Int J
Colorectal Dis 2012;27:595–600.
59. Panés J, García-Olmo D, Van Assche G, et al. Long-term efﬁ-
cacy and safety of stem cell therapy (Cx601) for complex peri-
anal ﬁstulas in patients with Crohn’s disease. Gastroenterology
2018;154:1334–1342.e4.
60. Duijvestein M, Vos ACW, Roelofs H, et al. Autologous bone
marrow-derived mesenchymal stromal cell treatment for re-
fractory luminal Crohn’s disease: results of a phase I study. Gut
2010;59:1662–1669.
61. Hawkey CJ, Allez M, Clark MM, et al. Autologous hematopoetic
stem cell transplantation for refractory crohn disease: a ran-
domized clinical trial. JAMA 2015;314:2524–2534.
Reprint requests
Address requests for reprints to: Benjamin Pariente, Hôpital Claude Huriez,
Université Lille 2, Gastroenterology, 1 rue Michel Polonovsky, 59000 Lille,
France. e-mail: benjamin.pariente@chru-lille.fr.
Conﬂicts of interest
These authors disclose the following: Benjamin Pariente has served a speaker
or consultant, and/or on the advisory board for Abbvie, Ferring, MSD, Takeda,
Hospira, Janssen, Pﬁzer, Biogaran; and received funding from Abbvie, Jans-
sen. Silvio Danese has served as a speaker or consultant, and/or on the
advisory board for Abbvie, Ferring, Hospira, Johnson and Johnson, Janssen,
Merck, MSD, Takeda, Mundipharma, Pﬁzer, Tigenix, UCB Pharma, Vifor, Bio-
gen, Celgene, Allergan, Celltrion, Sandoz, and Boehringer Ingelheim. Florian
Rieder has served as a speaker or consultant, and/or on the advisory board for
UCB, Celgene, Samsung, Roche, Pliant, Thetis, Boehringer-Ingelheim,
Helmsley, RedX, Abbvie, and Receptos; and has received funding from NIH,
ECCO, Pliant, UCB, and Receptos. Edouard Louis has served as a speaker or
consultant, and/or on the advisory board for Abbott, Abbvie, AstraZeneca,
Ferring, MSD, Chiesi, Falk, Takeda, Hospira, Janssen, Pﬁzer, Mitsubishi
Pharma, Celltrion, and Celgene; and has received funding from Takeda, Pﬁzer,
Abbvie, and MSD. The remaining authors disclose no conﬂicts.0 September 2018  3:08 pm  ce OB
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
